Sitagliptin/metformin: Difference between revisions
Content deleted Content added
spam |
add ref, remove yet more low quality refs |
||
| Line 28: | Line 28: | ||
| KEGG = D10261 |
| KEGG = D10261 |
||
}} |
}} |
||
'''Sitagliptin/metformin''' (trade name '''Janumet''') is an [[anti-diabetic drug]], being a [[combination drug]] of [[sitagliptin]] (a [[dipeptidyl peptidase-4 inhibitor]]) and [[metformin]]. |
'''Sitagliptin/metformin''' (trade name '''Janumet''') is an [[anti-diabetic drug]], being a [[combination drug]] of [[sitagliptin]] (a [[dipeptidyl peptidase-4 inhibitor]]) and [[metformin]]. It is used a third-line treatment for people who do not achieve control of their blood sugar with metformin alone, or after trying to add [[sulfonylurea]], [[pioglitazone]], or [[insulin]] to the treatment.<ref>{{cite journal |last1=Hayes |first1=J |last2=Anderson |first2=R |last3=Stephens |first3=JW |title=Sitagliptin/metformin fixed-dose combination in type 2 diabetes mellitus: an evidence-based review of its place in therapy. |journal=Drug design, development and therapy |date=2016 |volume=10 |pages=2263-70 |doi=10.2147/DDDT.S93076 |pmid=27486305 |pmc=4958358}}</ref> |
||
{{gastrointestinal-drug-stub}} |
{{gastrointestinal-drug-stub}} |
||
| Line 35: | Line 35: | ||
{{Portal|Pharmacy and Pharmacology}} |
{{Portal|Pharmacy and Pharmacology}} |
||
{{Commons category|Sitagliptin metformin}} |
{{Commons category|Sitagliptin metformin}} |
||
*[https://druginfo.nlm.nih.gov/drugportal/rn/1011232-08-8 U.S. National Library of Medicine: Drug Information Portal – Janumet] |
|||
*[https://www.drugs.com/janumet.html Janumet Uses, Dosage & Side Effects - Drugs.com] |
|||
{{DEFAULTSORT:Sitagliptin metformin}} |
{{DEFAULTSORT:Sitagliptin metformin}} |
||
Revision as of 18:23, 3 September 2018
| Combination of | |
|---|---|
| Sitagliptin | Dipeptidyl peptidase-4 inhibitor |
| Metformin | Biguanide |
| Clinical data | |
| Routes of administration | Oral |
| ATC code | |
| Legal status | |
| Legal status |
|
| Identifiers | |
| KEGG | |
Sitagliptin/metformin (trade name Janumet) is an anti-diabetic drug, being a combination drug of sitagliptin (a dipeptidyl peptidase-4 inhibitor) and metformin. It is used a third-line treatment for people who do not achieve control of their blood sugar with metformin alone, or after trying to add sulfonylurea, pioglitazone, or insulin to the treatment.[1]
 | This drug article relating to the gastrointestinal system is a stub. You can help Wikipedia by expanding it. |
External links
Wikimedia Commons has media related to Sitagliptin metformin.
- ^ Hayes, J; Anderson, R; Stephens, JW (2016). "Sitagliptin/metformin fixed-dose combination in type 2 diabetes mellitus: an evidence-based review of its place in therapy". Drug design, development and therapy. 10: 2263–70. doi:10.2147/DDDT.S93076. PMC 4958358. PMID 27486305.
{{cite journal}}: CS1 maint: unflagged free DOI (link)